|
|
Vaccine Detail
|
Allogeneic Multipotent Adult Progenitor Cells |
| Vaccine Information |
- Vaccine Name: Allogeneic Multipotent Adult Progenitor Cells
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007231
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Preparation: MAPC were seeded onto fibronectin (5 ng/mL)-coated flasks and cultured in MAPC maintenance medium for 3 days at 37°C and 3% O2. After 3 days, the medium was replaced by osteogenic differentiation medium (LoGuidice et al., 2016).
- Description: A biologic product that consists of undifferentiated stem cells, obtained from adult bone marrow or other non-embryonic tissue sources, that are expanded in vitro and deposited in master cell banks for ""off-the-shelf"" use, with potential hematopoiesis-inducing and immunomodulating activities. Allogeneic multipotent adult progenitor cells (MAPCs) are non-immunogenic due to the lack of major histocompatibility (MHC) molecule expression, and so elicit no immune response upon administration. In vivo, bone marrow-derived adult stem cells are capable of maturing into a broad range of cell types and may help restore the immune system by producing multiple therapeutic molecules in response to inflammation and tissue damage. This cancer vaccine can be used in multiple types of cancer. (NCIT_C77874).
|
| Host Response |
|
|
| References |
LoGuidice et al., 2016: LoGuidice A, Houlihan A, Deans R. Multipotent adult progenitor cells on an allograft scaffold facilitate the bone repair process. Journal of tissue engineering. 2016; 7; 2041731416656148. [PubMed: 27493716].
NCIT_C77874: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77874]
|
|
